Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zerobase is a paraffin-based emollient cream indicated for the symptomatic treatment of red, inflamed, damaged, or dry skin associated with conditions such as atopic eczema and dermatitis. The formulation contains liquid paraffin (11% w/w) and white soft paraffin (10% w/w), which function as occlusive agents to provide a protective barrier on the skin surface, thereby reducing transepidermal water loss (TEWL) and promoting hydration of the stratum corneum. Originally part of the Cambridge Laboratories portfolio, the brand was acquired by Alliance Pharma in 2010 and is currently manufactured by Thornton & Ross. It is widely used in the UK as a standard-of-care emollient, often serving as a reference control in clinical trials evaluating newer humectant- or ceramide-based topical therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zerobase.